Synonym
Moclobemide-d4; Moclobemide d4;
IUPAC/Chemical Name
4-chloro-N-(2-morpholinoethyl)benzamide-2,3,5,6-d4
InChi Key
YHXISWVBGDMDLQ-RHQRLBAQSA-N
InChi Code
InChI=1S/C13H17ClN2O2/c14-12-3-1-11(2-4-12)13(17)15-5-6-16-7-9-18-10-8-16/h1-4H,5-10H2,(H,15,17)/i1D,2D,3D,4D
SMILES Code
ClC1=C(C([2H])=C(C([2H])=C1[2H])C(NCCN2CCOCC2)=O)[2H]
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
272.77
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Moclobemide. 2021 May 17. PMID: 30000824.
2: Forgerini M, Schiavo G, Lucchetta RC, Mastroianni PC. Drug interactions for elderly people with mental and behavioral disorders: a systematic scoping review. Arch Gerontol Geriatr. 2021 Mar-Apr;93:104283. doi: 10.1016/j.archger.2020.104283. Epub 2020 Nov 7. PMID: 33227533.
3: Behlke LM, Lenze EJ, Carney RM. The Cardiovascular Effects of Newer Antidepressants in Older Adults and Those With or At High Risk for Cardiovascular Diseases. CNS Drugs. 2020 Nov;34(11):1133-1147. doi: 10.1007/s40263-020-00763-z. PMID: 33064291; PMCID: PMC7666056.
4: Bahji A, Ermacora D, Stephenson C, Hawken ER, Vazquez G. Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: A systematic review and network meta-analysis. J Affect Disord. 2020 May 15;269:154-184. doi: 10.1016/j.jad.2020.03.030. Epub 2020 Mar 20. PMID: 32339131.
5: Rothmore J. Antidepressant-induced sexual dysfunction. Med J Aust. 2020 Apr;212(7):329-334. doi: 10.5694/mja2.50522. Epub 2020 Mar 15. PMID: 32172535.
6: Bandelow B. Current and Novel Psychopharmacological Drugs for Anxiety Disorders. Adv Exp Med Biol. 2020;1191:347-365. doi: 10.1007/978-981-32-9705-0_19. PMID: 32002937.
7: Potměšil P. What combinations of agomelatine with other antidepressants could be successful during the treatment of major depressive disorder or anxiety disorders in clinical practice? Ther Adv Psychopharmacol. 2019 Jul 7;9:2045125319855206. doi: 10.1177/2045125319855206. PMID: 31312426; PMCID: PMC6614940.
8: Ziegler C, Domschke K. Epigenetic signature of MAOA and MAOB genes in mental disorders. J Neural Transm (Vienna). 2018 Nov;125(11):1581-1588. doi: 10.1007/s00702-018-1929-6. Epub 2018 Sep 21. PMID: 30242487.
9: Chokka PR, Hankey JR. Assessment and management of sexual dysfunction in the context of depression. Ther Adv Psychopharmacol. 2018 Jan;8(1):13-23. doi: 10.1177/2045125317720642. Epub 2017 Jul 31. PMID: 29344340; PMCID: PMC5761906.
10: Bandelow B, Michaelis S, Wedekind D. Treatment of anxiety disorders. Dialogues Clin Neurosci. 2017 Jun;19(2):93-107. doi: 10.31887/DCNS.2017.19.2/bbandelow. PMID: 28867934; PMCID: PMC5573566.
11: Riederer P, Müller T. Use of monoamine oxidase inhibitors in chronic neurodegeneration. Expert Opin Drug Metab Toxicol. 2017 Feb;13(2):233-240. doi: 10.1080/17425255.2017.1273901. Epub 2017 Jan 1. PMID: 27998194.
12: Finberg JP, Rabey JM. Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology. Front Pharmacol. 2016 Oct 18;7:340. doi: 10.3389/fphar.2016.00340. PMID: 27803666; PMCID: PMC5067815.
13: Saka C. An Overview of Analytical Methods for the Determination of Monoamine Oxidase Inhibitors in Pharmaceutical Formulations and Biological Fluids. Crit Rev Anal Chem. 2017 Jan 2;47(1):1-23. doi: 10.1080/10408347.2014.964835. Epub 2016 Oct 7. PMID: 27715253.
14: Narowska D, Bożek M, Krysiak K, Antczak J, Holka-Pokorska J, Jernajczyk W, Wichniak A. Frequent difficulties in the treatment of restless legs syndrome - case report and literature review. Psychiatr Pol. 2015;49(5):921-30. English, Polish. doi: 10.12740/PP/35395. PMID: 26688843.
15: Orhan IE. Potential of Natural Products of Herbal Origin as Monoamine Oxidase Inhibitors. Curr Pharm Des. 2016;22(3):268-76. doi: 10.2174/1381612822666151112150612. PMID: 26561069.
16: Pathak A, Srivastava AK, Singour PK, Gouda P. Synthetic and Natural Monoamine Oxidase Inhibitors as Potential Lead Compounds for Effective Therapeutics. Cent Nerv Syst Agents Med Chem. 2016;16(2):81-97. doi: 10.2174/1871524915666150624120516. PMID: 26104056.
17: Waldinger MD. Psychiatric disorders and sexual dysfunction. Handb Clin Neurol. 2015;130:469-89. doi: 10.1016/B978-0-444-63247-0.00027-4. PMID: 26003261.
18: Calandre EP, Rico-Villademoros F, Slim M. An update on pharmacotherapy for the treatment of fibromyalgia. Expert Opin Pharmacother. 2015 Jun;16(9):1347-68. doi: 10.1517/14656566.2015.1047343. PMID: 26001183.
19: Bandelow B, Reitt M, Röver C, Michaelis S, Görlich Y, Wedekind D. Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol. 2015 Jul;30(4):183-92. doi: 10.1097/YIC.0000000000000078. PMID: 25932596.
20: Naoi M, Riederer P, Maruyama W. Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression. J Neural Transm (Vienna). 2016 Feb;123(2):91-106. doi: 10.1007/s00702-014-1362-4. Epub 2015 Jan 22. PMID: 25604428.
